Acute treatment of migraine headaches

Seminars in Neurology

Volumn 30, Issue 2, 2010, Pages 145-153

  Taylor, Frederick R ^a,b  

^a PARK NICOLLET INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Central sensitization; Early intervention; Migraine ACT; Migraine specific

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; BUTALBITAL; DIHYDROERGOTAMINE; ELETRIPTAN; FROVATRIPTAN; INDOMETHACIN PLUS PROCHLORPERAZINE PLUS CAFFEINE; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TREXIMET; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ACUPUNCTURE; ACUTE DISEASE; ALLODYNIA; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG COST; DRUG INDUCED HEADACHE; EARLY INTERVENTION; HEADACHE; HUMAN; MIGRAINE; MIGRAINE ASSESSMENT OF CURRENT THERAPY; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; TRUST;

ACUTE DISEASE; ANALGESIA; ANTI-INFLAMMATORY AGENTS; DIHYDROERGOTAMINE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; NEUROPHARMACOLOGY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; TRYPTAMINES;

EID: 77950468652     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1249223     Document Type: Review

References (86)

1. Scary E. The Body in Pain: The Making and Unmaking of the World. New York Oxford University Press 2001 140
2. Lipton R B., Stewart W F. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999 39 (Suppl 2) S20-S26
3. Dodick D W. Applying the benefits of the AwM study in the clinic. Cephalalgia 2008 28 (Suppl 2) 42-49
4. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004 24 (Suppl 1) 1-160
5. Diamond M L. The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology 2002 58 (9, Suppl 6) S3-S9
6. Lipton R B., Diamond S, Reed M, Diamond M L., Stewart W F. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001 41 (7) 638-645 (Pubitemid 32777746)
7. Lipton R B., Cady R K., Stewart W F., Wilks K, Hall C. Diagnostic lessons from the spectrum study. Neurology 2002 58 (9, Suppl 6) S27-S31
8. Stewart W F., Lipton R B., Kolodner K. Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 2003 43 (3) 258-265
9. Ware J E., Bjorner J B., Dahlof C et al. Development for the headache impact test (HIT) using item response theory (IRT). Cephalalgia 2000 20 309 (Abstract)
10. Kroenke K, Spitzer R L., Williams J B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001 16 (9) 606-613
11. Lipton R B., Hahn S R., Cady R K. et al. In-office discussions of migraine: results from the American Migraine Communication Study. J Gen Intern Med 2008 23 (8) 1145-1151
12. Buse D C., Rupnow M F., Lipton R B. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 2009 84 (5) 422-435
13. Maizels M, Burchette R. Rapid and sensitive paradigm for screening patients with headache in primary care settings. Headache 2003 43 (5) 441-450
14. Dowson A J., Lipscombe S, Sender J, Rees T, Watson D, MIPCA Migraine Guidelines Development Group. Migraine In Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002 18 (7) 414-439
15. Dowson A J., Sender J, Lipscombe S et al. Establishing principles for migraine management in primary care. Int J Clin Pract 2003 57 (6) 493-507
16. Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004 62 (5) 788-790
17. Tepper S J., Spears R C. Acute treatment of migraine. Neurol Clin 2009 27 (2) 417-427
18. Bigal M E., Serrano D, Buse D, Scher A, Stewart W F., Lipton R B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008 48 (8) 1157-1168
19. Bigal M E., Lipton R B. Excessive acute migraine medication use and migraine progression. Neurology 2008 71 (22) 1821-1828
20. Dodick D W., Schwedt T. Headache: challenging conventional wisdom. Lancet Neurol 2009 8 (1) 12-14
21. Taylor F R. Migraine headache: options for acute treatment. Curr Neurol Neurosci Rep 2005 5 (2) 86-92
22. Lipton R B., Stewart W F., Stone A M., Linez M J., Sawyer J P., Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000 284 (20) 2599-2605
23. Lofland J H., Kim S S., Batenhorst A S. et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001 76 (11) 1093-1101
24. Halpern M T., Lipton R B., Cady R K., Kwong W J., Marlo K O., Batenhorst A S. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002 42 (10) 984-999
25. Garca Rodrguez L A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 343 (8900) 769-772
26. Tannenbaum H, Davis P, Russell A S. et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. CMAJ 1996 155 (1) 77-88
27. Griffin M R. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998 104 23S-29S
28. Fored C M., Ejerblad E, Lindblad P et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001 345 (25) 1801-1808
29. Lipton R B., Raskin N, Ruoff G, Saper J, Sheftell F, Solomon S. Over-the-counter analgesics and kidney disease. Am J Kidney Dis 1996 27 (6) 917-918
30. Soldin O P., Tonning J M., Obstetric-Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. N Engl J Med 2008 358 (20) 2185-2186
31. Shapiro R E., Tepper S J. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007 47 (2) 266-269
32. Evans R W. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. MedGenMed 2007 9 (3) 48
33. Evans R W. More on serotonin syndrome associated with triptan monotherapy. N Engl J Med 2008 359 (8) 870 author reply 870-871
34. Wenzel R G., Tepper S, Korab W E., Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother 2008 42 (11) 1692-1696
35. American Headache Society Committee on Headache Education. What is serotonin syndrome and what should you know about it? Available at: http//www.achenet.org/education/patients Accessed June 25, 2009
36. American Headache Society Committee on Headache Education. SSRIs, triptans and serotonin syndrome: what is the risk of serotonin syndrome in migraine? Available at: http//www.achenet.org/education/news/index.asp Accessed June 25, 2009
37. Dodick D, Lipton R B., Martin V et al., Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004 44 (5) 414-425
38. Dodick D W., Martin V T., Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004 44 (Suppl 1) S20-S30
39. Tepper S J., Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003 2 (2) 123-132
40. Headache Consortium US. American Academy of Neurology Headache Guidelines. Available at: http://www.aan.com/professionals/practice/pdfs/gl0087. pdf Accessed June 26, 2009
41. Snow V, Weiss K, Wall E M. et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002 137 840-849
42. Bedell A W., Cady R K., Diamond M L. et al. Patient-centered strategies for effective management of migraine. Primary Care Network 2000
43. Taylor F, Hutchinson S, Graff-Radford S, Cady R, Harris L. Diagnosis and management of migraine in family practice. J Fam Pract 2004 January (Suppl) S3-S24
44. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008 21 (3) 331-337
45. Cady R K., Sheftell F, Lipton R B. et al. Effects of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. Clin Ther 2000 22 1035-1048
46. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002 42 (1) 28-31
47. Goadsby P J. The Act when Mild (AwM) Study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 2008 28 (Suppl 2) 36-41
48. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia 2004 24 (Suppl 1) 94-97
49. Dowson A J., Tepper S J., Baos V, Baudet F, D'Amico D, Kilminster S. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 2004 20 (7) 1125-1135 (Pubitemid 38954475)
50. Garca M L., Baos V, Linez M, Pascual J, Lpez-Gil A. Responsiveness of migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache 2008 48 (9) 1349-1355
51. Cevoli S, D'Amico D, Martelletti P et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 2009 29 (12) 1285-1293
52. Ferrari M D., Roon K I., Lipton R B., Goadsby P J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 358 (9294) 1668-1675
53. Davies G M., Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000 20 (6) 554-560
54. Lipton R B., Stewart W F., Cady R K. et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000 40 (10) 783-791
55. Cady R K., Lipton R B., Hall C, Stewart W F., O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000 40 (10) 792-797
56. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003 43 (1) 44-48
57. Rapoport A M., Tepper S J. Triptans are all different. Arch Neurol 2001 58 (9) 1479-1480
58. Rapoport A M., Tepper S J., Bigal M E., Sheftell F D. The triptan formulations: how to match patients and products. CNS Drugs 2003 17 (6) 431-447
59. Sheftell F D., Feleppa M, Tepper S J., Volcy M, Rapoport A M., Bigal M E. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004 44 (7) 661-668
60. Living E. On megrim, sick-headache, and some allied disorders. A contribution to the pathology of nerve storms (1873). Nijmegen, The Netherlands Arts & Boeve Publishers 1997
61. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil B J., Bajwa Z H. An association between migraine and cutaneous allodynia. Ann Neurol 2000 47 (5) 614-624
62. Burstein R, Levy D, Jakubowski M, Woolf C J. Peripheral and central sensitization related to headache In: Olesen J, Welch KMA, Goadsby PJ, Tfelt-Hansen P The Headaches. Philadelphia, PA Lippincott Williams & Wilkins 2005 119-126
63. Burstein R, Cutrer M F., Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000 123 (Pt 8) 1703-1709
64. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004 101 (12) 4274-4279
65. Edelmayer R M., Vanderah T W., Majuta L et al. Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol 2009 65 (2) 184-193
66. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 55 (1) 19-26
67. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004 55 (1) 27-36
68. Burstein R. Almotriptan efficacy in migraine with developing allodynia is as high as the efficacy in migraine without allodyniabut is it the same in migraine with established allodynia? Headache 2009 49 (3) 364-365
69. Jakubowski M, Levy D, Kainz V, Zhang X C., Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007 148 (2) 573-583
70. Fox A W., Davis R L. Migraine chronobiology. Headache 1998 38 (6) 436-441
71. Graud G, Keywood C, Senard J M. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003 43 (4) 376-388
72. Dodick D W., Lipton R B., Ferrari M D. et al. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr Pain Headache Rep 2004 8 (6) 435-442
73. Dodick D W., Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004 24 (6) 417-424
74. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009 49 (6) 817-825
75. Brandes J L., Kudrow D, Stark S R. et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007 297 (13) 1443-1454
76. Sandrini G, Cerbo R, Del Bene E et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract 2007 61 (8) 1256-1269
77. Saper J R. What matters is not the differences between triptans, but the differences between patients. Arch Neurol 2001 58 (9) 1481-1482
78. Saper J R., Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006 46 (Suppl 4) S212-S220
79. Fisher M, Gosy E J., Heary B, Shaw D. Dihydroergotamine nasal spray for relief of refractory headache: a retrospective chart review. Curr Med Res Opin 2007 23 (4) 751-755
80. Aurora S K., Rozen T D., Kori S H., Shrewsbury S B. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009 49 (6) 826-837
81. Krymchantowski A V., Jevoux Cda C. The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migrainea review. Recent Patents CNS Drug Discov 2007 2 141-144
82. Azzopardi T D., Brooks N A. Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine. Ann Pharmacother 2008 42 (3) 397-402
83. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008 48 (3) 379-384
84. Lake A E. III. Behavioral and nonpharmacologic treatments of headache. Med Clin North Am 2001 85 (4) 1055-1075
85. Li Y, Liang F, Yang X et al. Acupuncture for treating acute attacks of migraine: a randomized controlled trial. Headache 2009 49 (6) 805-816
86. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med 2009 June 24 [Epub ahead of print]